Prematurely ended - Statement

EudraCT Number:	2012-001209-26
Full title of the study:	Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants in the acute treatment of therapy-resistant Depression. An open randomized study in a Simon-phase-II-design.
Sponsor-Code:	01032012/ Travel -Study (Tranylcypromin vs. Lithiumaugmentation)
Sponsor:	Charité – Universitätsmedizin Berlin
Principal Investigator:	Dr. med Roland Ricken Klinik für Psychiatrie (CCM) Charitéplatz 1, 10117 Berlin roland.ricken@charite.de
Product:	Jatrosom N/ ARISTO Pharma GmbH Quilonum retard/ Teofarma S.r.l., Germany
Date of early termination:	2024-02-23
Statement:	The trial will be terminated before inclusion of the planned number of patients because of difficulties in recruitment and lack of financial resources. During and after the SARS COV2-pandemic situation the recruitment-network of the study did not recruit enough study-participants anymore. We could not solicit enough financial support to restart the network and complete recruitment.

Dr. med. Roland Ricken

Principal Investigator Travel-Studie

Facharzt für Psychiatrie und Psychotherapie